It’s not a mystery, it’s medicine.
Comprehensive Cancer Centers of Nevada has developed a comprehensive research program that offers patients access to more than 170 Phase I, Phase II and Phase III clinical research trials annually. With breakthrough clinical research trials being discovered every day, it’s important to choose a practice that has clinical research top of mind.
What is clinical research?
Cancer research, or clinical research trials, is studies that involve people and test new ways to prevent, detect, diagnose, or treat cancer and other diseases.
Comprehensive always works to bring the latest advances in cancer to patients as quickly as possible. Among Comprehensive’s recent clinical trial milestones that continue to impact cancer patients worldwide:
- Immunotherapy research, or immuno-oncology, is the development of a compound that prevents a cancer cell’s over-expressed PD-1 or PD-L1 protein from putting the immune system to sleep. This form of treatment was approved by the FDA in 2015 and Comprehensive was among the first sites in the country to host trials dedicated to specific cancers.
- In May 2016, Tecentriq – (or atezolizumab) became the first drug to be approved by the FDA to treat advanced bladder cancer in more than 30 years. A Comprehensive patient was the first in the United States to receive the commercial cancer medicine.
- Atezolizumab is FDA-approved to treat lung and bladder cancer and is hopefully going to receive FDA approval to treat other cancers. Comprehensive was originally one of only six centers in the U.S. for “first in-human” testing and, in 2014; the FDA named the treatment a “breakthrough therapy” before subsequently fully approving it for bladder cancer.
- Comprehensive participated in the Phase III study of Xofigo®, an intravenous radiation injection to treat prostate cancer patients with bone metastases. Prior to receiving FDA approval in 2013, Comprehensive was one of the initial four sites in the United States offering the trial to patients.
- Comprehensive was the first clinic in the United States to spearhead research of PROVENGE, which is utilized to treat prostate cancer. In 2010, the Food and Drug Administration approved the use of PROVENGE® and Comprehensive administered the first treatment in Nevada. Leading up to this milestone, more than 100 patients were on PROVENGE®, traveling from Montana, Idaho, Arizona and states throughout the Mid-Atlantic region.
To date, Comprehensive Cancer Centers of Nevada has played a role in developing more than 60 FDA-approved cancer therapies.
For more information about our comprehensive research program, click here. To schedule an appointment, call 702-952-3350.